The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

San Francisco’s public health director, who oversaw the city’s responses to the COVID-19 pandemic and fentanyl crisis, ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

Between a third and a half of the populations of the four UK nations had not had the recommended number of COVID vaccinations and boosters by summer 2022, according to the first research study to look ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant ...

According to Dr. Dawn Nolt, a pediatric infectious disease physician at Oregon Health and Science University, many of the ...

Human metapneumovirus (hMPV) is one of the viruses that causes the common cold. It usually makes people only mildly poorly, ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

The second possibility is that Covid has now settled into a rut, which will see it become progressively milder until it ...

Insomnia is a common symptom with or after COVID. This article explains the multiple factors that contribute to “coronasomnia ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...